Can Prostate Cancer Cause Anemia?

Prostate cancer can cause anemia, and it does so frequently in advanced stages of the disease. In one cohort study of men with advanced prostate cancer, over half had anemia, with causes ranging from the cancer itself to the treatments used against it. The relationship is more tangled than a simple yes-or-no answer suggests, because the disease, the body’s inflammatory response, and the therapies all contribute through different pathways, sometimes simultaneously.

How Common Is Anemia in Men With Prostate Cancer?

In early-stage, localized prostate cancer, anemia is not especially common. The cancer is typically slow-growing and confined, and it does not disrupt the body’s blood-making machinery in a major way. But as the disease progresses, the picture changes. A study of men with advanced prostate cancer found that about 52% had anemia, and an additional 21% had iron deficiency even without yet meeting the threshold for anemia.¹ The more advanced the disease, the more likely anemia becomes. Men with metastatic disease (cancer that has spread beyond the prostate) and those on hormone-lowering treatments both face roughly double the odds of developing it.

This makes anemia one of the most frequent complications in advanced prostate cancer, not a rare side effect. Yet it often gets less attention than pain, urinary symptoms, or bone fractures. Fatigue is the symptom men and their doctors most commonly notice first, and it is easy to attribute that fatigue to the cancer itself or to aging rather than to a treatable drop in red blood cells.

How the Disease Itself Drives Down Red Blood Cells

The cancer does not need to directly invade the bone marrow to cause anemia, though it can do that too. There are several distinct mechanisms, and a man with advanced prostate cancer may have more than one operating at the same time.

Chronic inflammation: Prostate cancer, like many cancers, triggers a persistent inflammatory state. The body produces inflammatory signaling molecules that, among other things, ramp up production of a protein called hepcidin. Hepcidin acts as a gatekeeper for iron: when levels are high, iron gets locked inside storage cells and cannot be used to make new red blood cells. The result is a form of anemia where the body has iron but cannot access it.² This “anemia of chronic disease” accounted for roughly 40% of anemia cases in one study of advanced prostate cancer patients.¹
Bone marrow infiltration: Prostate cancer has a strong preference for spreading to bone. When cancer cells colonize the bone marrow, they physically crowd out the stem cells responsible for producing red blood cells, white blood cells, and platelets. This is sometimes called a “myelophthisic” process, and it can produce a distinctive pattern on blood tests where immature red and white blood cells spill into the circulation.³
Nutritional decline: Advanced cancer often suppresses appetite and changes metabolism. Deficiencies in iron, vitamin B12, and folate can each independently cause anemia. Among men with advanced prostate cancer and anemia, about 14% had iron-deficiency anemia, 7% had B12 deficiency, and 16% had folate deficiency.¹

One case report illustrated how intertwined these factors can be. A man with prostate cancer and severe iron-deficiency anemia did not respond well to iron supplements alone. Imaging revealed a prostate tumor that was producing hepcidin directly, essentially locking iron away from his bone marrow. His anemia improved only after anti-androgen therapy shrank the tumor and reduced its hepcidin output.⁴ Cases like this underscore why simply taking iron pills is sometimes not enough when cancer is the underlying driver.

How Treatment Itself Can Cause Anemia

Here is where the picture gets uncomfortable: many of the standard treatments for prostate cancer also lower red blood cell counts. So a man who was not anemic before starting treatment may become anemic because of it, and a man who was already mildly anemic may get worse.

Androgen Deprivation Therapy

Testosterone stimulates the bone marrow to produce red blood cells. When you suppress testosterone with hormone therapy, a cornerstone of advanced prostate cancer treatment, red blood cell production drops. A study examining the mechanism found that ADT directly reduces the proliferation of the bone marrow’s red-blood-cell-making progenitor cells. Nine of the men in that study developed new-onset anemia after starting hormone therapy.⁵ This is not an unusual complication; it is a predictable biological consequence of lowering androgens, and it contributes significantly to the fatigue that men on these drugs so frequently report.

Chemotherapy and Radionuclide Therapy

Chemotherapy drugs like docetaxel, used in advanced prostate cancer, are broadly toxic to fast-dividing cells, and the bone marrow is full of them. Anemia, along with low white blood cell and platelet counts, is among the most common side effects of chemotherapy.

Radium-223, a targeted radioactive treatment for bone metastases, presents its own hematologic risks. In a real-world study of elderly men receiving radium-223, about 37% developed anemia, and anemia was the most frequent reason men had to stop treatment early.⁶ The risk was higher in men with a greater disease burden and in those who had previously received chemotherapy. The pivotal clinical trial for radium-223 showed fewer blood-related side effects overall, but trial patients tend to be healthier and more carefully selected than the broader population who ends up receiving the drug.⁷

Why Anemia Matters Beyond Fatigue

It is tempting to think of anemia as a secondary nuisance, something that makes you tired but does not change the trajectory of the cancer. The evidence says otherwise.

A systematic review pooling data from multiple studies found that men with metastatic castration-resistant prostate cancer who were anemic had significantly worse survival compared to those who were not. The increase in mortality risk ranged from about 55% to 82%, depending on the study design.⁸ A separate analysis of newly diagnosed metastatic prostate cancer patients confirmed that lower hemoglobin at diagnosis independently predicted shorter survival and a weaker response to hormonal therapy.⁹

Anemia may also undermine other treatments. Radiation therapy depends partly on oxygen to damage cancer cells. When hemoglobin is low, less oxygen reaches the tumor, and the hypothesis is that this anemia-related oxygen shortage could make the cancer more resistant to radiation.¹⁰ This remains an active area of investigation, but it adds to the case that anemia is not just a symptom to endure. It may actively interfere with treatment effectiveness.

For men receiving radium-223 for bone metastases, having a hemoglobin level below 10 g/dL before starting treatment was associated with worse cancer outcomes and a greater need for blood transfusions during and after therapy. Researchers have suggested that the benefit of radium-223 is limited in men who are already significantly anemic.¹¹

Sorting Out What Is Causing the Anemia

Because there are so many possible contributors, figuring out why a man with prostate cancer is anemic takes some detective work. A standard blood count will confirm the anemia, but the underlying cause determines the treatment. Iron studies can distinguish true iron deficiency from the “locked-away iron” pattern of chronic-disease anemia. B12 and folate levels identify nutritional gaps. A blood smear can show abnormal cell shapes that hint at bone marrow infiltration or, rarely, autoimmune destruction. Kidney function tests matter too, since prostate cancer can sometimes obstruct the urinary tract and damage the kidneys, reducing their output of erythropoietin, the hormone that tells the bone marrow to make red blood cells.³

The timing of the anemia provides useful context. Anemia that appears soon after starting hormone therapy points strongly to ADT as the culprit. Anemia developing weeks after a chemotherapy cycle is likely treatment-related myelosuppression. Anemia that is present at the time of cancer diagnosis, or that worsens as disease progresses despite stable treatment, raises suspicion for the cancer itself, whether through marrow infiltration, chronic inflammation, or both.

Managing Anemia in Prostate Cancer

Treatment depends entirely on the cause, and in many cases there is more than one cause to address.

When a specific deficiency is identified, replacing what is missing is the first step. Iron supplements, B12 injections, or folate can correct nutritional anemias. But as the hepcidin case described earlier illustrates, iron supplementation may not work if the underlying problem is that the cancer is blocking iron absorption or utilization. In those situations, treating the cancer more effectively can sometimes resolve the anemia as a secondary benefit.

Blood transfusions remain the fastest way to raise hemoglobin in severe cases. In a study of advanced cancer patients receiving palliative care, about 36% of transfusion episodes produced noticeable symptomatic improvement within two weeks, with fatigue and dizziness being the symptoms most likely to improve.¹² That means roughly a third of the time, transfusions meaningfully help with symptoms, but they are not a permanent fix. The benefit is temporary, and repeated transfusions carry their own risks and logistical burdens.

Erythropoiesis-stimulating agents (drugs that mimic the natural hormone erythropoietin to boost red blood cell production) have a complicated history in cancer care. A large meta-analysis found that these drugs reduced the need for transfusions but increased the risk of blood clots by roughly 50-70% and, in some analyses, were associated with a small increase in overall mortality during the treatment period.¹³ A separate meta-analysis reached a somewhat more reassuring conclusion on mortality, finding no statistically significant effect on death or disease progression, but confirmed the elevated clot risk.¹⁴ The disagreement between these analyses reflects genuine uncertainty, and current guidelines generally restrict these drugs to specific situations, typically chemotherapy-induced anemia in patients not being treated with curative intent, where the goal is to avoid transfusions.

Rare but Striking Autoimmune Anemias

In uncommon cases, prostate cancer triggers the immune system to attack the body’s own red blood cells. This is called autoimmune hemolytic anemia, and it falls under the umbrella of paraneoplastic syndromes: conditions caused not by the tumor’s physical presence but by the immune disruption it creates.

Several case reports document this phenomenon. One involved a man with prostate cancer who developed warm autoimmune hemolytic anemia after a routine blood transfusion. His immune system began rapidly destroying both transfused and native red blood cells, confirmed by a strongly positive direct antiglobulin test. With no autoimmune disease or culprit drug identified, the hemolytic anemia was attributed to the cancer’s disruption of normal immune regulation.¹⁵ Another report described a man with both bladder and prostate cancer who developed warm antibody hemolytic anemia during radiation therapy for his prostate cancer.¹⁶ A third case involved Evans syndrome, a condition combining hemolytic anemia with low platelets, occurring in a man whose prostate cancer had undergone small-cell transformation.¹⁷

These are rare, but they matter because autoimmune hemolytic anemia requires different treatment than the other forms. Standard iron replacement or transfusion alone will not fix a situation where the immune system is destroying red blood cells as fast as they appear. Treatment typically involves immunosuppressive drugs, and in some cases, effectively treating the underlying cancer resolves the immune dysregulation that started the problem. When a man with prostate cancer develops sudden, unexplained anemia with signs of red blood cell destruction (elevated bilirubin, low haptoglobin, elevated lactate dehydrogenase), a paraneoplastic autoimmune process should be on the differential even though it is uncommon in solid tumors.

When Anemia Appears Before a Prostate Cancer Diagnosis

Most discussion of prostate cancer and anemia centers on men who already know they have cancer. But anemia can sometimes be among the earliest signs of undiagnosed disease, particularly when the cancer is aggressive or has already spread by the time it is found. The case report of the man with iron-deficiency anemia that turned out to be driven by a hepcidin-producing prostate tumor is a vivid example: no bleeding source could be found, iron supplements were not working, and the anemia only made sense once the cancer was discovered.⁴

This is not the typical presentation. Most prostate cancer is detected through PSA screening or incidental findings long before it is advanced enough to cause systemic effects like anemia. But in men who present with unexplained anemia, especially older men with iron-deficiency anemia that does not respond to supplementation and has no clear gastrointestinal bleeding source, clinicians sometimes consider the possibility of an occult malignancy, and prostate cancer is among the cancers on that list.

Anemia in metastatic castration-resistant prostate cancer has been specifically linked to worse overall and progression-free survival.⁸ Whether correcting the anemia itself improves survival, or whether anemia is simply a marker of more aggressive or widespread disease, remains an open question. The existing evidence on erythropoiesis-stimulating agents, as noted earlier, has not convincingly shown a survival benefit from pharmacologically boosting hemoglobin in cancer patients. That leaves treating the cancer itself as the most reliable way to address the root cause, when the cancer is the root cause, though supportive measures like transfusions and nutritional correction remain important for quality of life while the primary treatment takes effect.

1
Hong Kong Medical Journal. Anaemia and iron deficiency in advanced prostate cancer: revisiting a common morbidity
2
PubMed Central. Hepcidin, anaemia, and prostate cancer
3
PubMed Central. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment
4
Cureus. Iron-Deficiency Anemia Associated With Prostate Cancer, and Ameliorated by Anti-androgen Therapy
5
PubMed Central. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer
6
PubMed Central. Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience
7
PubMed. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations
8
PubMed Central. Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis
9
PubMed. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894
10
International Journal of Radiation Oncology, Biology, Physics. Prevalence and Correlates of Anemia in Prostate Cancer Patients Treated With Radiotherapy
11
Journal of Clinical Oncology. Impact of pre-existing anemia and/or packed red blood cell transfusion prior to Radium-223 administration on oncologic outcomes
12
PubMed Central. Transfusion practices in patients with advanced cancer: a retrospective study in a palliative care service
13
PubMed Central. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
14
British Journal of Cancer. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
15
PubMed Central. Warm Autoimmune Hemolytic Anemia Unmasked by Blood Transfusion in a Patient With Prostate Cancer: A Case Report
16
PubMed Central. Paraneoplastic hemolytic anemia associated with prostate cancer. A case report
17
PubMed Central. Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation